Lord Freyberg – 2016 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Lord Freyberg on 2016-07-19.

To ask Her Majesty’s Government what steps they are taking to ensure that patients suffering with radioactive iodine-refractory differentiated thyroid cancer are not denied treatment due to the timeframes applied by NHS England for access to the new Cancer Drugs Fund.

Lord Prior of Brampton

NHS England has advised that systemic therapy is available for patients with radioiodine-refractory thyroid cancer through the continued funding of sorafenib for this indication via the Cancer Drugs Fund. The National Institute for Health and Care Excellence has been asked to develop technology appraisal guidance on the use of sorafenib and lenvatinib for this indication.